All In Biotech

Drugs by condition

Drugs approved for iga nephropathy

Brand-name prescription drugs and biologics whose FDA label lists iga nephropathy as an approved use. Matched on the label phrases: "IgA nephropathy", "immunoglobulin A nephropathy".

Last checked: Nov 19, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations

Brand-name drugs approved

7

Still marketed, NDA or BLA

Drug classes

4

Novel drugs

6

New molecular entities and new biologics

In development

31

Investigational drugs in Phase 2 or 3

Newest approvals

The most recently first-approved brand-name drugs for iga nephropathy.

  • Trutakna (Atacicept-Vymj) · Vera Therapeutics Inc. NovelPriority reviewJul 7, 2026
  • Voyxact (Sibeprenlimab-Szsi) · Otsuka Pharm CO LTD NovelBreakthrough therapyAccelerated approvalPriority reviewNov 25, 2025
  • Vanrafia (Atrasentan Hydrochloride) · Novartis NovelAccelerated approvalApr 2, 2025
  • Fabhalta (Iptacopan Hydrochloride) · Novartis NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanDec 5, 2023
  • Filspari (Sparsentan) · Travere NovelAccelerated approvalPriority reviewOrphanFeb 17, 2023

All approved drugs for iga nephropathy, by class

Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 0 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.

Endothelin Receptor Antagonist (1)

Complement Inhibitor (1)

  • Ultomiris Ravulizumab-Cwvz · Alexion Pharm · 2018

Corticosteroid (1)

  • Tarpeyo Budesonide · Calliditas · 2021

Class not listed in FDA's data (4)

  • Trutakna Atacicept-Vymj · Vera Therapeutics Inc. · 2026
  • Voyxact Sibeprenlimab-Szsi · Otsuka Pharm CO LTD · 2025
  • Vanrafia Atrasentan Hydrochloride · Novartis · 2025
  • Fabhalta Iptacopan Hydrochloride · Novartis · 2023

Drugs in development for iga nephropathy

Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.

Search the pipeline
  • FelzartamabPhase 38 trials

    Biogen · Antibody-mediated Rejection, Microvascular Inflammation, Graves' Disease

  • TelitaciceptRC18, RC18-LPhase 38 trials

    RemeGen Co., Ltd. · CTD-ILD, Primary Sjogren's Disease, Sjögren's Disease

  • PovetaciceptALPN-303Phase 37 trials

    Vertex Pharmaceuticals · Immunoglobulin A Nephropathy, Myasthenia Gravis, Generalized, Primary Membranous Nephropathy

  • CM313Phase 36 trials

    Keymed Biosciences Co.Ltd · Systemic Lupus Erythematosus, Primary Immune Thrombocytopenia, Platelet Transfusion Refractoriness

  • FUB523zigakibart, BION-1301Phase 36 trials

    Novartis · IgA Nephropathy, Immunoglobulin A Nephropathy, IgA Nephropathy (IgAN)

  • HRS-5965Phase 36 trials

    Chengdu Suncadia Medicine Co., Ltd. · Primary IgA Nephropathy, Paroxysmal Nocturnal Hemoglobinuria

  • HSK39297Phase 35 trials

    Haisco Pharmaceutical Group Co., Ltd. · IgA Nephropathy (IgAN), Paroxysmal Nocturnal Hemoglobinuria, Paroxysmal Nocturnal Haemoglobinuria (PNH)

  • MY008211APhase 35 trials

    Wuhan Createrna Science and Technology Co., Ltd · Paroxysmal Nocturnal Hemoglobinuria (PNH), Paroxysmal Nocturnal Hemoglobinuria, IgA Nephropathy (IgAN)

  • NTQ5082Phase 34 trials

    Nanjing Chia-tai Tianqing Pharmaceutical · Paroxysmal Nocturnal Hemoglobinuria, Primary IgA Nephropathy

  • SCTC21CPhase 34 trials

    Sinocelltech Ltd. · IgA Nephropathy, Multiple Myeloma (MM), Systemic Lupus Erythematosus (SLE)

  • JADE101Phase 32 trials

    Jade Biosciences, Inc. · IgA Nephropathy (IgAN), IgA Nephropathy

  • BHV-1400Phase 31 trial

    Biohaven Therapeutics Ltd. · IgA Nephropathy

  • Alpine Immune Sciences Inc, A Subsidiary of Vertex · Immunoglobulin A Nephropathy

  • SC0062Phase 31 trial

    Biocity Biopharmaceutics Co., Ltd. · IgA Nephropathy (IgAN)

  • SefaxersenRO7434656Phase 31 trial

    Roche (Genentech) · Primary IgA Nephropathy

  • NM8074Phase 28 trials

    NovelMed Therapeutics · Paroxysmal Nocturnal Hemoglobinuria, Dermatomyositis, PNH - Paroxysmal Nocturnal Hemoglobinuria

  • SHR-2173Phase 25 trials

    Guangdong Hengrui Pharmaceutical Co., Ltd · Generalized Myasthenia Gravis, Active Lupus Nephritis, Primary IgA Nephropathy

  • HSK39297 200mgQDPhase 23 trials

    Haisco Pharmaceutical Group Co., Ltd. · IgA Nephropathy (IgAN), Lupus Nephritis (LN)

  • HS-10542Phase 22 trials

    Jiangsu Hansoh Pharmaceutical Co., Ltd. · IgAN, Immunoglobulin A Nephropathy (IgAN), Glomerular Disease

  • HSK39297 300mgQDPhase 22 trials

    Haisco Pharmaceutical Group Co., Ltd. · IgA Nephropathy (IgAN), Lupus Nephritis (LN)

More on iga nephropathy: recruiting trials · published research

Related in kidney and urology: Chronic kidney disease · Overactive bladder · Enlarged prostate (BPH) · Erectile dysfunction

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.